Physician profile
Drew Weissman
NPI 1760579601
$12,845,707.89
in general payments reported to CMS, 2019-2025
7 companies · $13M in 2025
The $13M reported for 2025 was more than what 99% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,632 · 2020: $20.50 · 2021: $1,163 · 2022: $1,936 · 2023: $2,500 · 2025: $13M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $13M · Consulting Fee: $8,379 · Travel and Lodging: $845 · Food and Beverage: $45.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $12,826,686.37 |
| Consulting Fee | $8,379.12 |
| Travel and Lodging | $844.76 |
| Food and Beverage | $45.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,826,686.37 | 2025 | |
| Sanofi US Services INC. | $6,632.06 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $5,879.12 | 2025 | |
| Pfizer INC. | $2,780.43 | 2022-2025 | |
| Biontech Se | $2,673.41 | 2021-2023 | |
| Sanofi Pasteur INC. | $1,036.00 | 2021 | |
| Alfasigma USA, INC. | $20.50 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Weissman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.